Drugs / HS135
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06581159 | Jan → Jul 2025 | diastolic heart failure, pulmonary hypertension | 35Pharma Inc | Terminated | No outcome recorded |
| Phase 1 | NCT06493461 | Oct 2024 → Mar 2025 | pulmonary arterial hypertension | 35Pharma Inc | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS135 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06581159 ↗ |
| Route | Subcutaneous | “dosed subcutaneously” NCT06493461 ↗ |